Emerging research suggests that GLP-1 drugs — Zepbound is one such treatment — not only reduce food cravings but may also suppress desires for other substances. Yet, so far, no pharma ...

After slashing the U.S. prices of several of its insulin products by 75% at the start ... Like most other companies that had drugs on the list of 10 that are subject to early price negotiations ...

A federal jury has sided with Insulet, which claimed that the South Korea-based diabetes tech company EOFlow had stolen trade secrets related to its wearable insulin pump, in a case that ...

Insulet sued EOFlow last year. Its lawsuit said EOFlow hired away former Insulet employees to develop its EOPatch, an insulin device similar to Insulet's Omnipod. After failing for six years to ...